Related Experiment Video
Updated: Aug 16, 2026
Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma
Published on: January 22, 2022
[Selecting postoperative chemotherapy regimen and optimizing therapy cycle for stage II-IV ovarian epithelial
Yong-Wen Huang1, Yu-Jie Li, Meng-Da Li
1Skate Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.
Background & Objective:
The postoperative chemotherapy for ovarian epithelial carcinoma need to be improved. This study was conducted to seek suitable chemotherapy for patients with stage II-IV ovarian epithelial carcinoma.
Methods:
The records of 325 patients with stage II-IV ovarian epithelial carcinoma, received different postoperative chemotherapy (HCBP, CP, CBP, or CAP) regimens for different cycles from Jan. 1986 to Dec. 2000 in our cancer center, were analyzed retrospectively. The treatment outcome and prognosis of these patients were analyzed.
Results:
The 5-year survival rate of the patients received HCBP regimen was significantly higher than those of the patients received CP, CBP, or CAP regimens (84.3% vs. 43.0%, P=0.008; 46.1%, P=0.016; and 40.0%, P=0.002). The incidence of chemotherapy-related complications was significantly lower in the patients received CP regimen than in the patients received HCBP, CBP, or CAP regimens (76.0% vs. 91.3%, P=0.015; 88.2%, P=0.043; and 87.7%, P=0.038). The 5-year survival rates of the patients received more than 6 or 5-6 cycles were significantly higher than that of the patients received less than 5 cycles (56.2% or 59.5% vs. 35.1%, P< 0.001). The incidences of chemotherapy-related complications in such patients were 89.6%, 81.1%, and 82.8% (P=0.214), respectively.
Conclusions:
We recommend 5-6 cycles of CP-based chemotherapy regimens for stage II-IV ovarian epithelial carcinoma. Prolonging the duration of each chemotherapy cycle might achieve good prognosis.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:34Inhibition of Cdk Activity